Price
No data yet.
Social Signal Score
Analyst Ratings
16 analystsRevenue
$182.43M+56.83%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Edward Cotterell
- Sector
- Technology
- Industry
- Information Technology Services
- Employees
- 11,225
- Beta
- 1.03
- Country
- GB
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- -0.00
Financials
Revenue
$182.43M+56.8%Net Income
$-403.04M-3311.5%EBITDA
$-368.96M-1969.2%Free Cash Flow
$-5.57M-1604.4%EPS (diluted)
$-7.71-3184.0%Shares Outstanding (diluted)
52.23M+2.3%Operating Expenses
$34.36MCash & Debt
$48.58MReturn of Capital
$2.56MRevenue by Segment (annual)
$620.09MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $772.25M | $21.21M | $0.36 |
| 2024 | $740.76M | $17.12M | $0.29 |
| 2023 | $794.73M | $94.16M | $1.64 |
| 2022 | $654.76M | $83.09M | $1.48 |
| 2021 | $446.30M | $43.45M | $0.79 |
| 2020 | $350.95M | $19.99M | $0.37 |
| 2019 | $287.93M | $24.01M | $0.44 |
| 2018 | $217.61M | $18.98M | $0.38 |
| 2017 | $159.37M | $16.83M | $0.32 |
| 2016 | $115.43M | $16.71M | $0.32 |
| 2015 | $84.11M | $13.55M | $0.29 |
| 2014 | $63.91M | $8.15M | $0.16 |
| 2013 | $42.61M | $4.75M | $0.12 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DAVA's reported EPS growth of 9.6% a year over 12 years.
- EPS in 5 years
- $0.57
- Implied price
- $17.79
- Return from $1.92
- 56.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $8.84 — today's price is already 78.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -0.4% | 31.2% | 36.9% | 41.8% | 46.2% | 50.0% |
| 4.6% | 37.8% | 43.8% | 49.0% | 53.5% | 57.5% |
| 9.6% | 44.4% | 50.7% | 56.1% | 60.8% | 65.1% |
| 14.6% | 51.0% | 57.6% | 63.2% | 68.2% | 72.6% |
| 19.6% | 57.6% | 64.4% | 70.3% | 75.5% | 80.1% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50-37.50%Social Signal Score
Mentions (7)
- Newsbusinesswire.com·4d ago·Negative
DAVA Investors Have Opportunity to Lead Endava plc Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $DAVA--DAVA Investors Have Opportunity to Lead Endava plc Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsbusinesswire.com·6d ago·Negative
DAVA Investors Have Opportunity to Join Endava plc Fraud Investigation with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $DAVA--DAVA Investors Have Opportunity to Join Endava plc Fraud Investigation with SBS Law.
View source ↗ - Newsprnewswire.com·10d ago·Neutral
Endava plc (NYSE: DAVA) Scrutinized Amid Board Placing CFO On Leave, 25% Stock Drop -- HBSS SAN FRANCISCO, Sept. 25, 2026 /PRNewswire/ -- Investors in Endava (NYSE: DAVA) saw the price of their shares tumble over 25% on September 22, 2026 after the company revealed serious management and potential accounting problems.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Endava plc (NYSE: DAVA) Scrutinized Amid Board Placing CFO On Leave, 25% Stock Drop -- HBSS SAN FRANCISCO, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Investors in Endava (NYSE: DAVA) saw the price of their shares tumble over 25% on September 22, 2026 after the company revealed serious management and potential accounting problems.
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Securities Fraud Investigation Into Endava plc (DAVA) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Endava plc (“Endava” or the “Company”) (NYSE: DAVA) on behalf of investors concerning the Company's possible violations of federal securities laws.
View source ↗ - Newsbusinesswire.com·14d ago·Neutral
Endava Appoints Conor McShane as Interim Chief Financial Officer LONDON--(BUSINESS WIRE)--Endava plc (NYSE: DAVA), the technology-driven business transformation group whose AI-native approach combines cutting-edge technology with deep industry expertise, today announced that Conor McShane of AlixPartners LLP, a leading global business advisory firm, has been appointed as Interim Chief Financial Officer, effective today. Mr. McShane's appointment follows the decision of the Company's Board of Dir…
View source ↗ - Newsglobenewswire.com·55d ago·Negative
LeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast Cancer BOTHELL, Wash., Aug. 12, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that its lead product candidate, lasofoxifene, will be featured in multiple presentations at Dava Oncology's
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $0.14 per share
Typical surprise +4.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, May 21$0.07 vs $0.27miss
- Thu, Feb 19$0.22 vs $0.21beat
- Tue, Nov 11$0.20 vs $0.25miss
- Thu, Sep 4$0.33 vs $0.32beat
- Wed, May 14$0.44 vs $0.40beat
- Thu, Feb 20$0.38 vs $0.32beat
Estimates and results for DAVA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DAVA officers and directors.
- Bought
- —
- Sold
- $12k
0 trades
8 trades
- Butcher Patricksold
- Hollister Kathryn Asold
- Pattillo David Alexandersold
- Druskin Bensold
- Pattillo David Alexandersold
- Hollister Kathryn Asold
- Druskin Bensold
- Butcher Patricksold
60 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jun 9, 2025 (24d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (23d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Jul 9, 2024 (21d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed May 15, 2024 (30d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 7, 2024 (24d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 11, 2023 (26d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 15, 2023 (30d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 17, 2022 (33d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 17, 2022 (44d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Nov 15, 2021 (45d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2021 (19d later)Sell$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Aug 9, 2021 (17d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Jan 11, 2021 (25d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (21d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Dec 15, 2020 (32d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Nov 5, 2020 (7d later)Buy$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Oct 14, 2020 (15d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 13, 2020 (19d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.